论文部分内容阅读
自1993年发现幽门螺杆菌（HP）以来,大量的研究资料表明,幽门螺杆菌（HP）是消化性溃疡.慢性胃炎及胃粘膜相关性淋巴组织样淋巴瘤的主要致病因素之一,与胃癌的发生有密切关系。故根除HP是防治这些疾病的重要措施之一。目前幽门螺杆菌根除治疗的方案众多,但对方案中每日给药次数对杀HP影响的报告甚少,现以薛惠平[1]报道的以H2受体为基础的三联疗法,把西咪替丁以不同给药方案作随机地照,旨在探索,服的次数少,方便的方
Since the discovery of Helicobacter pylori (HP) in 1993, a large number of studies have shown that Helicobacter pylori (HP) is a peptic ulcer, one of the main causative agents of chronic gastritis and gastric mucosa-associated lymphoid tissue lymphoma, and The occurrence of gastric cancer is closely related. Therefore, eradicating HP is one of the important measures to prevent these diseases. At present, there are many solutions for H. pylori eradication treatment, but there are few reports on the impact of daily administration on HP in the scheme. Now, based on H2 receptor-based triple-triple therapy reported by Xue Huiping [1] D given in different programs randomly for photos, aims to explore, the number of services less convenient side